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Maintenance of Long-Term Clinical Benefit With
Sirolimus-Eluting Coronary Stents
Three-Year Results of the RAVEL Trial
Jean Fajadet, MD; Marie-Claude Morice, MD; Christoph Bode, MD; Paul Barragan, MD;
Patrick W. Serruys, MD; William Wijns, MD; Constantino R. Constantini, MD;
Jean-Léon Guermonprez, MD; Hélène Eltchaninoff, MD; Didier Blanchard, MD;
Antonio Bartorelli, MD; Gert-Jan Laarman, MD; MarcoAntonio Perin, MD; J. Eduardo Sousa, MD;
Gerhard Schuler, MD; Ferenc Molnar, MD; Giulio Guagliumi, MD; Antonio Colombo, MD;
Ernesto Ban Hayashi, MD; Egon Wülfert, BPharm
Background—The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of
restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). This analysis
examined whether these beneficial effects persist over the longer term.
Methods and Results—This multicenter trial randomly assigned 238 patients to revascularization of single, de novo, native
coronary artery lesions with sirolimus-eluting versus conventional bare-metal stents. Survival free from target lesion
revascularization (TLR), target vessel failure (TVF), and MACE up to 3 years of follow-up was compared between the
2 treatment groups. Complete data sets were available in 94.2% of patients treated with sirolimus-eluting stents and in
94.1% of patients randomized to the control group. The cumulative 1-, 2-, and 3-year event-free survival rates were
99.2%, 96.5%, and 93.7% for TLR and 95.8%, 92.3%, and 87.9% for TVF, respectively, in the sirolimus-eluting stent
group, versus 75.9%, 75.9%, and 75.0% for TLR and 71.2%, 69.4%, and 67.3% for TVF in the control group (P0.001
for both comparisons at 3 years). Rates of MACE at 3 years were 15.8% in patients randomly assigned to
sirolimus-eluting stents versus 33.1% in patients assigned to bare-metal stents (P0.002). One patient treated with a
sirolimus-eluting stent died of a cardiac cause between 12 and 36 months.
Conclusions—Treatment of de novo coronary stenosis with sirolimus-eluting stents was associated with a sustained
clinical benefit and very low rates of TLR and of other MACE up to 3 years after device implantation. (Circulation.
2005;111:1040-1044.)
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The inclusion of stents in a large percentage of percuta-neous coronary revascularization procedures has fueled
vigorous investigative efforts focused on the prevention of
in-stent restenosis. Among the various strategies explored,
the development of drug-eluting stents has been particularly
promising.1 Stents coated with sirolimus (rapamycin), a
macrolide antifungal agent with antiproliferative and immu-
nosuppressant properties that inhibits regulators of cell-cycle
progression and migration of vascular smooth muscle cells,2–4
See p 958
effectively prevented the development of neointimal proliferation
and injury-induced arterial intimal thickening in preclinical stud-
ies5–8 and that of in-stent restenosis in human pilot studies.9
Furthermore, in randomized trials comparing sirolimus-eluting with
conventional bare-metal stents, very low rates of in-stent restenosis
were observed at 6 to 8 months of follow-up in the groups treated
with drug-eluting stents.10–13 These remarkable angiographically
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documented results were corroborated by very low rates of major
adverse cardiac events (MACE) at 1 year.10
The purpose of this analysis was to examine whether this
favorable effect on clinical events observed in the RAVEL
trial (Randomized Study with the Sirolimus-Coated Bx Ve-
locity Balloon-Expandable Stent in the Treatment of Patients
with de Novo Native Coronary Artery Lesions) persisted
beyond 1 year.
Methods
Patient Selection
The design and detailed methods of this randomized, double-blind
clinical trial have been published previously.10 In brief, the 238
randomized patients had stable or unstable angina pectoris14,15 or
silent ischemia caused by a single de novo coronary lesion (51% to
99% diameter stenosis) in a vessel between 2.5 and 3.5 mm in
diameter. Major exclusion criteria included evolving myocardial
infarction, a 50% stenosis in an unprotected left main coronary
artery, an ostial target lesion, a calcified lesion that could not be
successfully predilated with an angioplasty balloon, or an angio-
graphically visible thrombus within the target lesion.
The study was reviewed and approved by each participating
institution’s Ethical Review Committee, and all patients signed a
written informed consent before enrollment.
Study Procedures
After successful predilatation of the target lesion, patients were
randomly assigned 1:1 in a double-blind manner to a conventional
bare-metal Bx Velocity balloon-expandable stent or a sirolimus-
eluting, Cypher balloon-expandable stent (Cordis Corp, Johnson &
Johnson). Postdilatation was performed as necessary. Procedural
success was defined as attainment of a 30% vessel diameter
stenosis and freedom from in-hospital MACE after implantation of
the assigned study device.
Patient Follow-Up
Patients returned for yearly follow-up evaluations to monitor the
possible interim development of angina or MACE. Follow-up
angiography with quantitative coronary angiography was performed
systematically at 18030 days as described previously.10 Because of
the double-blind nature of the study, the decision to perform further
target lesion or vessel revascularization after the 6-month angio-
graphic follow-up was left to the investigator’s discretion, by
protocol design.
Study End Points and Definitions
The primary angiographic end point of the trial was in-stent late
luminal loss at 6 months, ascertained by quantitative coronary
angiography.10 The primary clinical end point of the study was a
composite of MACE at 6 months, defined as cardiac or noncardiac
death, Q-wave and non–Q-wave myocardial infarction, coronary
artery bypass graft, or target lesion revascularization (TLR). A TLR
was adjudicated as being “clinically driven” by the independent
Clinical Events Committee on the basis of the presence of a 50%
diameter stenosis on the 6-month angiogram in the presence of signs
or symptoms of myocardial ischemia or a70% diameter stenosis in
the absence of ischemia. Target-vessel failure (TVF) was defined as
any revascularization of the index vessel, myocardial infarction, or
death that could not be unequivocally attributed to a vessel other than
the index vessel.
Statistical Analyses
All analyses were based on the intention-to-treat principle. For
continuous variables, differences between the treatment groups were
evaluated by ANOVA or Wilcoxon’s rank-sum test. For discrete
variables, differences were expressed as counts and percentages and
were analyzed with Fisher’s exact test. Revascularization of the
target lesion or vessel and the composite of MACE during follow-up
were analyzed by the Kaplan-Meier method. Differences between
the event-free survival curves for the 2 groups were compared by use
of the Wilcoxon and log-rank tests. A 2-sided probability value of
P0.05 was considered statistically significant.
Results
The baseline clinical characteristics of the RAVEL trial
population have been described in detail previously10 and are
summarized in Table 1. Except for a significantly higher
percentage of men in the group treated with bare-metal stents,
the 2 study groups were similar with respect to all variables
examined. Complete data sets were available at 3 years in
94.2% of patients randomly assigned to sirolimus-eluting
stents and in 94.1% of patients randomized to the control
group. The number and percentages of patients who experi-
enced a MACE (Cypher, 15.8%, versus Bx Velocity, 33.1%)
through 3 years of follow-up are listed in hierarchical order in
Table 2, top, and nonhierarchical order in Table 2, bottom.
The incidence of MACE was significantly lower in the
recipients of sirolimus-eluting stents than in patients assigned
to conventional bare-metal stents. This lower MACE rate was
attributable primarily to fewer TLR procedures performed in
TABLE 1. Baseline Clinical and Angiographic Characteristics
of Overall Patient Population and Each Study Group
All Patients
(n238)
Sirolimus-Eluting
Stents
(n120)
Controls
(n118)
Mean age, y 60.710.4 61.810.7 59.710.1
Men 76 70 81‡
Previous MI 36 38 34
Diabetes mellitus 19 16 21
Treated hypercholesterolemia 40 38 43
Treated hypertension 61 62 61
Current smoker 30 27 33
Angina pectoris
Unstable* 51 48 52
Stable† 38 41 37
Silent ischemia 11 11 11
Target coronary artery
LAD 50 49 51
RCA 27 27 27
LCx 23 24 22
Lesion type
A 7 8 4
B1 37 39 35
B2 57 54 61
Reference vessel diameter, mm 2.620.53 2.600.54 2.640.52
Lesion length, mm 9.583.25 9.563.33 9.613.18
MI indicates myocardial infarction; RCA, right coronary artery; and LCx, left
circumflex artery. Values are meanSD or percentage of patients.
*Unstable angina was defined according to the system of Braunwald.15
†Stable angina was defined according to the system of the Canadian
Cardiovascular Society.14
‡P0.05 vs sirolimus-eluting stents; all other between-groups differences
are statistically nonsignificant.
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the sirolimus-eluting stent patients. The cumulative 1-, 2-,
and 3-year survival rates free from TLR were, respectively,
99.2%, 96.5%, and 93.7% in the group randomized to
sirolimus-eluting stents, versus 75.9%, 75.9%, and 75.0% in
the control group (log-rank P0.001; Wilcoxon P0.001;
Figure 1). Similarly, the cumulative 1-, 2-, and 3-year
survival rates free from TVF were, respectively, 95.8%,
92.3%, and 87.9% in the group randomized to sirolimus-
eluting stents, versus 71.2%, 69.4%, and 67.3% in the control
group (log-rank P0.001; Wilcoxon P0.001; Figure 2).
Finally, the corresponding cumulative MACE-free survivals
were 94.1%, 88.3%, and 83.7% in the sirolimus-eluting stent
group, versus 71.2%, 70.3%, and 66.4% in the control group
(log-rank P0.001; Wilcoxon P0.001; Figure 3). If only
the 1- to 3-year time interval is considered, the incidence of
clinically driven TLR was 4.2% in the sirolimus group and
1.7% in the control group (P0.45), whereas the incidence of
TVF was 5.9% versus 4.3% (P0.77), respectively.
Deaths During Follow-Up
At the end of 3 years, 9 patients had died in the group treated
with sirolimus-eluting stents, versus 5 patients in the control
group. Six noncardiac deaths occurred in the sirolimus group
in the second and third years of follow-up, because of cancer
(n2), intracranial hemorrhage (n2), respiratory failure
(n1), and pulmonary embolism (n1).
A single patient died of a cardiac cause in the actively
treated group 961 days after the stent implantation procedure.
The patient was hospitalized because of dyspnea and a
cardiac arrhythmia. The patient developed an infection in the
hospital that led to kidney failure and septicemia. The patient
died 4 days after admission. The Critical Event Committee
adjudicated the event as a “cardiac death” because there was
insufficient information about the cause of dyspnea and
arrhythmia. By contrast, 3 patients died suddenly in the
Figure 2. Survival free from TVF in the sirolimus-eluting stent
group (dark line) and the control group (shaded line). Error
bars1.5SE.
TABLE 2. MACE Recorded Up to 3 Years in the Actively
Treated (Sirolimus) vs the Control Group
Sirolimus
(n114)*
Controls
(n113)* P
Hierarchical order
Death 9 (7.9) 5 (4.4) NS
Cardiac 1 (0.9) 3 (2.7) NS
Noncardiac 8 (7.0) 2 (1.8) NS
Nonfatal MI 4 (3.5) 6 (5.3) NS
Q-wave 3 (2.6) 2 (1.8) NS
Non–Q-wave 1 (0.9) 4 (3.5) NS
All TLR 6 (5.3) 28 (24.8) 0.001
Surgical 2 (1.8) 1 (0.9) NS
Percutaneous 4 (3.5) 27 (23.9) 0.001
Clinically driven TLR 5 (4.4) 16 (14.2) 0.012
Surgical 2 (1.8) 0 NS
Percutaneous 3 (2.6) 16 (14.2) 0.002
All MACE 19 (16.7) 39 (34.5) 0.002
Nonhierarchical order
Death 9 (7.9) 5 (4.4) NS
Cardiac 1 (0.9) 3 (2.7) NS
Noncardiac 8 (7.0) 2 (1.8) NS
MI 6 (5.3) 8 (7.1) NS
Q-wave 3 (2.6) 3 (2.7) NS
Non–Q-wave 3 (2.6) 5 (4.4) NS
All TLR 7 (6.1) 29 (25.7) 0.001
Surgical 3 (2.6) 1 (0.9) NS
Percutaneous 5 (4.4) 28 (24.8) 0.001
Clinically driven TLR 6 (5.3) 17 (15.0) 0.016
Surgical 3 (2.6) 0 NS
Percutaneous 4 (3.5) 17 (15.0) 0.003
Target vessel revascularization† 2 (1.8) 3 (2.7) NS
Target vessel failure
(clinically driven target vessel
revascularization)
12 (10.5) 27 (23.9) 0.008
Target vessel failure (all target
vessel revascularization)
13 (11.4) 38 (33.6) 0.001
MI indicates myocardial infarction; MACE indicates any death, MI, or TLR;
and target vessel failure indicates cardiac death, MI, or TVR. Values indicate
numbers (%) of patients.
*nall collected 3-year follow-up data  patients with MACE event.
†For lesions other than the target lesion.
Figure 1. Survival free from TLR in the sirolimus-eluting stent
group (dark line) and the control group (shaded line). Error
bars1.5SE.
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control group of probable cardiac causes at 45, 517, and 1067
days, respectively, after the index revascularization
procedure.
Repeat Revascularization Procedures Between 12
and 36 Months in the Sirolimus-Eluting Stent Group
In the sirolimus-eluting stent group, 3 patients underwent
repeat clinically driven revascularization procedures in the
second and 3 patients in the third year of follow-up. The first
patient, a 68-year-old man, had undergone initial stent im-
plantation for stenosis of the left anterior descending coro-
nary artery (LAD). He developed recurrent angina pectoris at
14 months of follow-up and was found to have a 75% to 90%
restenosis of the index target lesion (in-stent) and a nearly
total occlusion of the right coronary artery. Both stenosis
were treated with sirolimus-eluting stents 455 days after the
index procedure. The same patient developed recurrent angi-
nal complaints, at which time angiography showed 10%
stenosis with TIMI III perfusion of the target lesion but
significant new lesions in the ramus branch, circumflex, and
right coronary arteries, which led to bypass surgery, including
bypass of the original target lesion, 644 days after the index
procedure. The second patient was a 51-year-old man who
developed unstable angina and underwent repeat stenting
after 468 days for a 70% in-segment restenosis of the target
lesion. The third patient, a 50-year-old man, was initially
treated for an LAD stenosis. He presented with recurrent
angina and underwent repeat percutaneous coronary revascu-
larization for a 70% in-segment stenosis at the distal edge of
the originally stented lesion at 608 days of follow-up. A
second stent was placed in the LAD, overlapping the first
stent located in the target lesion. The fourth patient, a
61-year-old man, developed silent ischemia due to a 70%
in-segment restenosis within 5 mm of the original target
lesion in the LAD and underwent repeat percutaneous angio-
plasty at 904 days of follow-up. A fifth patient underwent
multiple coronary artery bypass graft surgery at 1033 days of
follow-up 1 month after he had suffered an anteroinferior
myocardial infarction, attributed to occlusion of the target
vessel. The last patient developed unstable angina 3 years
after implantation of a sirolimus-eluting stent in the mid–right
coronary artery. He underwent implantation of a second stent
for a new 80% stenosis of the target vessel, outside the
original stent, at 1093 days of follow-up.
Finally, one additional patient, a 62-year-old woman en-
rolled in a RAVEL substudy, underwent a repeat, non–
clinically driven, percutaneous revascularization procedure at
551 days of follow-up, after a scheduled diagnostic angio-
gram was performed at 18 months of follow-up. She had
undergone initial stent implantation for treatment of angina
pectoris due to a 100% occlusion of the LAD. The follow-up
angiogram showed a 10% stenosis of the target lesion and an
aneurysm in its stented segment. Two additional stents were
implanted in the target vessel.
Discussion
The RAVEL trial was the first randomized, controlled trial to
demonstrate that sirolimus delivered from a stent over a 30-
to 45-day period could virtually eliminate restenosis after
angioplasty in patients with de novo coronary atherosclerotic
lesions. The very low 1-year rate of target lesion revascular-
ization observed in RAVEL has been corroborated in SIRIUS
(Multicenter, Randomized, Double-Blind Study of the
Sirolimus-Coated BX VELOCITY Balloon Expandable Stent
in the Treatment of Patients With De Novo Native Coronary
Artery Lesions), E-SIRIUS, and C-SIRIUS, larger trials that
enrolled subsets of patients at considerably higher risk of
restenosis than the RAVEL patient population.11–13 In light of
the observations made during longer-term follow-up in clin-
ical studies of several other antirestenosis agents,16–19 it is
imperative to demonstrate the absence of both late “catch-up”
restenosis and late stent thrombosis when evaluating new
strategies aimed at eliminating in-stent restenosis. This is the
first randomized, controlled trial of a drug-eluting stent to
demonstrate sustained safety and efficacy up to 3 years.
These findings, taken in conjunction with the previously
reported angiographic and intravascular ultrasound studies of
the sirolimus-eluting stents at earlier time points in RAVEL
and SIRIUS,10,11 and the uncontrolled angiographic and
intravascular ultrasound observations made up to 2 years after
implantation of sirolimus-eluting stents for de novo coronary
stenoses,20,21 and up to 1 year after treatment of in-stent
restenosis,22 confirm that neointimal hyperplasia is effec-
tively suppressed over the long term by sirolimus without
interfering with normal reendothelialization. Taken together,
these results should dispel the theoretical concerns regarding
the long-term biocompatibility of the drug-carrying polymer
or other unexpected processes promoting delayed inflamma-
tory, hyperplastic, or thrombotic complications with this
particular device.
Main Study Findings
The major finding of this study is that the highly significant,
absolute difference in the need for repeat TLR between
patients treated with sirolimus-eluting stents and patients
treated with bare-metal stents at 1 year (23.3%) remained
essentially unchanged at 3 years (18.7%). Equally important
is the observation that this reduced need for repeat revascu-
larization was not mitigated by an increased risk of short- or
long-term fatal or nonfatal cardiovascular events. Although
there were more deaths in the sirolimus-eluting stent group,
Figure 3. Survival free from MACE in the sirolimus-eluting stent
group (dark line) and the control group (shaded line). Error
bars1.5SE.
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all but one were due to noncardiac causes. The difference in
target vessel failure, an end point favored by the Food and
Drug Administration and the primary end point in the SIRIUS
trial, also remained highly significant (24.6% at 1 versus
21.4% at 3 years; P0.001). It is also particularly noteworthy
that these unprecedented results were obtained with only 2
months of treatment with aspirin plus clopidogrel or ticlopi-
dine and the administration of platelet glycoprotein IIb/IIIa
inhibitors in only 10% of patients.
In contradistinction to these long-term data from RAVEL,
the recently published TAXUS IV trial,23 with the paclitaxel-
eluting stent and a different polymer carrier, provides
follow-up data to 12-month follow-up. The RAVEL trial is
the first large-scale clinical study with a drug-eluting stent
reporting long-term follow-up to 3 years. Given the major
differences in drugs and polymers being used in different
drug-eluting stent systems either already approved or being
evaluated, as well as the significant failure of some other
systems that have not been approved for sale, it seems
prudent to evaluate the long-term outcomes of each new
drug-eluting stent system over several years and not assume
a class effect.
Limitations of the Study
Because it is not generally feasible to reevaluate patients
serially with invasive procedures, these 3-year results of the
RAVEL trial are limited to clinical end points. The absence of
progression of the neointimal hyperplastic process in these
patients was, therefore, inferred rather than directly ascer-
tained by angiography or intravascular ultrasound. However,
the meticulous observations made in 45 patients who under-
went both angiography and intravascular ultrasound up to 2
years in the FIM trial suggest that this assumption is
legitimate.20–22
Conclusions
The remarkable safety and efficacy of sirolimus-eluting
stents, documented angiographically and by intravascular
ultrasound at 6 months after device implantation in this trial,
were confirmed clinically up to 3 years after device
implantation.
Acknowledgment
This trial was sponsored by Cordis Corporation, a Johnson &
Johnson Company, Warren, NJ. The authors thank Rodolphe Ruffy,
MD, Dennis Donohoe, MD, and Brian Firth, MD, PhD, for their
assistance in the preparation of this manuscript.
References
1. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of reste-
nosis, II. Circulation. 2002;106:2859–2866.
2. Marx SO, Marks AR. Bench to Bedside. The development of rapamycin
and its application to stent restenosis. Circulation. 2001;104:852–855.
3. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits
cell cycle regulators of proliferation in VSMC. Circ Res. 1995;76:
412–417.
4. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR.
Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest.
1996;98:2277–2283.
5. Burke SE, Lubbers NL, Chen Y-W, Hsieh GC, Mollison KW, Luly JR,
Wegner CD. Neointimal formation after balloon-induced vascular injury
in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc
Pharmacol. 1999;33:829–835.
6. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham
ME, Morris RE. Treatment with rapamycin and mycophenolic acid
reduces arterial intimal thickening produced by mechanical injury and
allows endothelial replacement. Transplantation. 1995;59:655–661.
7. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S,
Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of
intimal thickening after balloon angioplasty in porcine coronary arteries
by targeting regulators of the cell cycle. Circulation. 1999;99:
2164–2170.
8. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R,
Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F,
Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces
neointimal formation in a porcine coronary model. Circulation. 2001;
104:1188–1193.
9. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF,
Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma
JJ, Serruys PW. Sustained suppression of neointimal proliferation by
sirolimus-eluting stents: one-year angiographic and intravascular
ultrasound follow-up. Circulation. 2001;104:2007–2011.
10. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R,
RAVEL Study Group. A randomized comparison of a sirolimus-eluting
stent with a standard stent for coronary revascularization. N Engl J Med.
2002;346:1773–1780.
11. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,
O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS,
Jaeger JL, Kuntz RE, SIRIUS Investigators. Sirolimus-eluting stents
versus standard stents in patients with stenosis in a native coronary artery.
N Engl J Med. 2003;349:1315–1323.
12. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E,
Breithardt G, E-SIRIUS Investigators. Sirolimus-eluting stents for
treatment of patients with long atherosclerotic lesions in small coronary
arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet.
2003;362:1093–1099.
13. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM,
Kuntz RE, Popma JJ, C-SIRIUS Investigators. The Canadian study of the
sirolimus-eluting stent in the treatment of patients with long de novo
lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol.
2004;43:1110–1115.
14. Campeau L. Grading for angina pectoris [letter]. Circulation. 1976;54:
522–523.
15. Braunwald E. Unstable angina: a classification. Circulation. 1989;80:
410–414.
16. Albiero R, Nishida T, Adamian M, Amato A, Vaghetti M, Corvaja N, Di
Mario C, Colombo A. Edge restenosis after implantation of high-activity
32P radioactive -emitting stents. Circulation. 2000;101:2454–2457.
17. Costa MA, Sabate M, van der Giessen WJ, Kay IP, Cervinka P, Ligthart JM,
Serrano P, Coen VL, Levendag PC, Serruys PW. Late coronary occlusion
after intracoronary brachytherapy. Circulation. 1999;100:789–792.
18. Grube E, Hauptmann K, Colombo A, DiSciascio G, Silber S, Bach R,
DiMario C, Reifart N, Fajadet J, Score Investigators. SCORE trial interim
safety results: despite efficacy, late stent thrombosis with the
QuaDDS-QP2 stent. J Am Coll Cardiol. 2002;39(suppl A):38A. Abstract.
19. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent
implantation. Heart. 2001;86:262–264.
20. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS,
Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW.
Two-year angiographic and intravascular ultrasound follow-up after
implantation of sirolimus-eluting stents in human coronary arteries. Cir-
culation. 2003;107:381–383.
21. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits
PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ.
Persistent inhibition of neointimal hyperplasia after sirolimus-eluting
stent implantation: long-term (up to 2 years) clinical, angiographic, and
intravascular ultrasound follow-up. Circulation. 2002;106:1610–1613.
22. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA,
Centemero M, Maldonado G, Abizaid AS, Pinto I, Falotico R, Jaeger J,
Popma JJ, Serruys PW. Sirolimus-eluting stent for the treatment of
in-stent restenosis: a quantitative coronary angiography and three-
dimensional intravascular ultrasound study. Circulation. 2003;107:
24–27.
23. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT,
Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME,
TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in
patients with coronary artery disease. N Engl J Med. 2004;350:221–231.
1044 Circulation March 1, 2005
 by guest on May 30, 2012http://circ.ahajournals.org/Downloaded from 
